Revance Therapeutics (RVNC) to Release Earnings on Wednesday

Revance Therapeutics (NASDAQ:RVNC) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Revance Therapeutics to post earnings of ($0.29) per share and revenue of $78.12 million for the quarter.

Revance Therapeutics Price Performance

RVNC stock opened at $3.65 on Monday. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.56. The firm has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. The business has a 50 day moving average of $3.42 and a 200 day moving average of $4.60.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday, November 8th. StockNews.com assumed coverage on Revance Therapeutics in a research report on Saturday. They set a “hold” rating for the company. Mizuho reduced their price objective on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. Barclays reduced their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Revance Therapeutics currently has an average rating of “Hold” and an average price target of $8.39.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.